NMRA · Neumora Therapeutics, Inc.
$1.61
+0.01 (+0.63%)
At close · Jul 17
Market Cap
$298.31M
Shares
185,284,244
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.61
Open$1.60
Day$1.59–1.72
52W$0.83–3.65
Avg vol 30d3.2M
Short int6.7M · 3.6% float · 1.1d
Short vol38%
Last earningsMar 30, 2026
DataSep 2023–Jul 2026
Filing10-Q · May 7
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.8 · elevated
Equity put/call 0.73
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−26%
below
Price vs 50-day avg
−6%
below
RSI (14)
48
neutral
MACD trend
Positive
52-week position
28%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+5%
trailing
6-month return
−22%
trailing
YTD return
−10%
this year
Relative strength
−30%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
3 of 109 funds reported for Jun 30 · net -3.5M sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.61% of float · ▲ +35.9% MoM · 1.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
109 holders — mid 3-yr range
Squeeze score
50
elevated · 0–100
Fundamentals
EPS growth
+5%
Y/Y
Free cash flow
$-206.6M
Balance sheet
$68.0M
net cash
Quant / Vol
risk profile
Volatility
128%
annualized · 1-yr
Max drawdown
−75%
past year
ATR
9.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−26%
Bearish
Price vs 50-day avg
−6%
Bearish
RSI (14)
48
Neutral
MACD trend
Positive
Bullish
52-week position
28%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
3 of 109 funds reported for Jun 30 · net -3.5M sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.61% of float · ▲ +35.9% MoM · 1.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
109 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $2 · 28%
52-wk high $4
vs 200-day avg -26%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NMRA
this stock
Neumora Therapeutics, Inc.
|
$298.31M | -10.1% | — | — | 3.6% |
|
ONC
BeOne Medicines Ltd.
|
$450.95B | +2.7% | +22179.2% | 917.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.26B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.94B | -12.2% | +20.8% | 16.5 | 3.3% |
|
ARGX
Argenx SE
|
$53.84B | +2.3% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
107
- % held
- 34.6%
- Reported
- 3 of 109
- Top holder
- Siren, L.L.C.
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NMRA | -4.2% | +5.2% | -21.8% | -5.3% | -10.1% |
| SPY | -1.5% | +0.3% | +7.8% | -0.5% | +9.0% |
| vs SPY | -2.6% | +4.9% | -29.7% | -4.8% | -19.1% |